Exact Sciences
EXAS
$50.38
Share price
-3.02%
Change (1 day)
-39.43%
Change (1 year)
Categories
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.
Exact Sciences (EXAS) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $3.32 B
According to Exact Sciences's latest financial reports the company's total liabilities are $3.32 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Exact Sciences - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $3.32 B | 4.47% |
| 2022-12-31 | $3.18 B | -3.44% |
| 2021-12-31 | $3.29 B | 22.6% |
| 2020-12-31 | $2.68 B | 120.87% |
| 2019-12-31 | $1.21 B | 44.44% |
| 2018-12-31 | $0.84 B | 978.91% |
| 2017-12-31 | $78.14 M | 87.19% |
| 2016-12-31 | $41.74 M | 12.3% |
| 2015-12-31 | $37.17 M | 55.93% |
| 2014-12-31 | $23.84 M | 110.77% |
| 2013-12-31 | $11.31 M | -16.36% |
| 2012-12-31 | $13.52 M | 0.49% |
| 2011-12-31 | $13.45 M | -19.71% |
| 2010-12-31 | $16.76 M | -14.82% |
| 2009-12-31 | $19.67 M | 136.18% |
| 2008-12-31 | $8.33 M | 0.29% |
| 2007-12-31 | $8.3 M | -6.77% |
| 2006-12-31 | $8.91 M | -32.62% |
| 2005-12-31 | $13.22 M | -27.05% |
| 2004-12-31 | $18.12 M | -19.26% |
| 2003-12-31 | $22.45 M | 91.3% |
| 2002-12-31 | $11.73 M | 183.98% |
| 2001-12-31 | $4.13 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $57.61 B | 1,632.19% | 🇫🇷 France |
 Veracyte VCYT | $70.8 M | -97.87% | 🇺🇸 USA |
 Myriad Genetics MYGN | $0.36 B | -89.08% | 🇺🇸 USA |
 Biocept
BIOC | $21.81 M | -99.34% | 🇺🇸 USA |